Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Buy” by Brokerages
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has been assigned an average rating of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among […]
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has been assigned an average rating of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among […]
